Status:
RECRUITING
Reinforcement Learning and Obsessive-compulsive Disorder: Exploring the Role of the Orbitofrontal Cortex
Lead Sponsor:
Fundacao Champalimaud
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18-65 years
Brief Summary
Obsessive-compulsive disorder (OCD) is a neuropsychiatric condition affecting 1-3% of the population. Typically, symptoms start in adolescence or early adulthood, are time-consuming, and have a signif...
Detailed Description
INTRODUCTION: Obsessive-compulsive disorder (OCD) is the fourth most common psychiatric disorder, characterized by recurrent and intrusive obsessive thoughts and/or compulsions that are distressing, ...
Eligibility Criteria
Inclusion
- Exclusively for the OCD group: established diagnosis of Obsessive-Compulsive Disorder according to DSM-5 criteria;
- Exclusively for the control group: does not meet DSM criteria for any of the psychiatric diagnoses screened by the Mini International Neuropsychiatric Interview;
- Age between 18 and 65 years-old;
- Fluent Portuguese or English speaker.
Exclusion
- Any acute medical illness;
- Substance abuse or dependence;
- Pregnancy;
- Dementia;
- Developmental disorders with low intelligence quotient or any other form of cognitive impairment;
- Active neurological disease;
- Previously known structural lesion of the central nervous system;
- Illiteracy or otherwise not understanding the study's instructions;
- Inability to give informed consent;
- Individuals presenting with any psychotic or mood disorder condition requiring hospitalization at that moment;
- For experiment 2, these exclusion criteria will be expanded by additional factors that specifically preclude TMS use.
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT06566781
Start Date
October 1 2019
End Date
December 31 2026
Last Update
August 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Champalimaud Foundation
Lisbon, Portugal, 1400-038